


IDIOPATHIC PULMONARY FIBROSIS (IPF)

GLOBAL CLINICAL TRIAL LANDSCAPE (2025)



#DYK
Did you know?



IPF is a progressive lung disease marked by lung tissue scarring and declining respiratory function



2022

13-20
AFFECTED INDIVIDUALS

OVER 1M
CASES GLOBALLY

The Asia-Pacific region showed variation, with **South Korea reporting the highest incidence**

In North America, **Canada recorded the highest incidence** and prevalence of IPF

In Europe, **Italy and France were among the most affected** countries, reflecting a significant regional burden



Emerging therapies reshape IPF treatment through RNAi, AI-designed drugs, prostacyclin analogs, and pathway inhibitors targeting fibrosis, inflammation, and disease progression



The **U.S. and Switzerland led IPF venture funding**, with contributions from China, South Korea, Japan, and India

IDIOPATHIC PULMONARY FIBROSIS (IPF) TRIAL CONTRIBUTIONS

Countries **Mainland China, the United States, Australia, and the United Kingdom**, emerged as top locations for conducting trials

Biomarkers are key to early, accurate IPF diagnosis and personalized treatment, advancing precision medicine in patient care

